WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has received notification from the Nasdaq Listings Qualifications Department that the Company’s market value of its listed shares was for 10 consecutive trading days below the $50 million minimum required for continued listing on the Nasdaq Global Market according to Marketplace Rule 4450(b)(1)(A). The Company also does not meet the alternative listing standard which requires $50 million in total assets and $50 million in total revenue in either the most recent fiscal year, or two of the three most recent fiscal years, according to Marketplace Rule 4450(b)(1)(B). There is no change in the trading of OSCI common stock on the Nasdaq Global Market at this time.
